ArriVent BioPharma, Inc. (AVBP) vs Kailera Therapeutics, Inc. (KLRA)

A side-by-side comparison of ArriVent BioPharma, Inc. and Kailera Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
ArriVent BioPharma, Inc. logo
AVBP
ArriVent BioPharma, Inc.
$580M
$12.46HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
Kailera Therapeutics, Inc. logo
KLRA
Kailera Therapeutics, Inc.
$1.40B
$10.78HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

Total return — AVBP vs KLRA

growth of $100 · dividends reinvested · last 1y
AVBP -4.0% (-4.0%/yr)KLRA -58.3% (-58.3%/yr)AVBP compounded faster over this window
406080100120Start $100$96$42
AVBP KLRA

AVBP vs KLRA: by the numbers

  • •KLRA is the larger company ($1.40B vs $580M market cap).

Metrics side by side

Valuation

MetricAVBPKLRA
P/B ratio1.581.25

Profitability

MetricAVBPKLRA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-44.63%N/A
ROIC-47.96%-24.52%

Go deeper

Full AVBP analysisFull KLRA analysisInteractive comparison tool

Dig into the metrics

ArriVent BioPharma ROEKailera Therapeutics ROEArriVent BioPharma operating marginKailera Therapeutics operating marginArriVent BioPharma revenue growthKailera Therapeutics revenue growthArriVent BioPharma free cash flowKailera Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.